AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 173 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $5,633,000 | +78.8% | 130,000 | +44.4% | 0.46% | +64.3% |
| Q3 2020 | $3,150,000 | -34.6% | 90,000 | 0.0% | 0.28% | -46.2% |
| Q2 2020 | $4,813,000 | +23.3% | 90,000 | -18.2% | 0.52% | -4.9% |
| Q1 2020 | $3,903,000 | -48.9% | 110,000 | -31.2% | 0.55% | -34.6% |
| Q4 2019 | $7,640,000 | -3.8% | 160,000 | -34.7% | 0.84% | -15.9% |
| Q3 2019 | $7,938,000 | -20.4% | 245,002 | +22.5% | 1.00% | -9.5% |
| Q2 2019 | $9,976,000 | +16.5% | 200,000 | +57.5% | 1.10% | +9.7% |
| Q1 2019 | $8,566,000 | +46.3% | 127,012 | 0.0% | 1.00% | +49.6% |
| Q4 2018 | $5,857,000 | -47.8% | 127,012 | -12.7% | 0.67% | -40.4% |
| Q3 2018 | $11,215,000 | -17.0% | 145,428 | -9.3% | 1.12% | -18.7% |
| Q2 2018 | $13,513,000 | +73.9% | 160,428 | +68.9% | 1.38% | +44.4% |
| Q1 2018 | $7,769,000 | +35.9% | 95,000 | -5.0% | 0.96% | +24.1% |
| Q4 2017 | $5,717,000 | +471.1% | 100,000 | +566.7% | 0.77% | +503.1% |
| Q3 2017 | $1,001,000 | – | 15,000 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
| Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
| Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
| BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
| Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
| Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
| Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
| BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
| Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
| HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |